Richter-Helm, a leading steadily growing Germany-based contract development and manufacturing organization (CDMO), offers excellent services in the continuously growing market of pharmaceutical biotechnology. Two additional bioreactors with capacities of 300 litres and 1,500 litres for microbial production will be added. This includes also the establishment of mid- and downstream processing and supporting utilities on a total area of about 10,000 m².
Leukopaks and cell products for research
Sponsored PublicationsCellex Group is an experienced facility worldwide for all kind of allogeneic and autologous stem cell collections and is, besides that, growing to become a complete service provider for cellular immunotherapy products. One essential area of the portfolio is Cell Community, the perfect solution for researchers in need of cell products.
COVAX: Pfizer and Biontech to provide 500 Million Doses of COVID-19 Vaccine
Latest NewsU.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022.
Variants will drive long-term COVID-19 vaccine
OpinionNew entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to catch up with demand.
Formulation development for ATMPS in high demand
Sponsored PublicationsAdvanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP development facilities to meet the increasing market demand.
Medical Cannabis in Europe – the next frontier
BackgroundThe cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term future outlook.
Oxurion: CFO now CEO
AppointmentsTom Graney, until now CFO of Belgian Oxurion nv, took over from CEO Patrik De Haes. De Haes becomes Non-executive Chairman of the Biopharmaceutical company, spezialised in retinal disorders.
Iksuda Therapeutics closes $47m financing round
Latest NewsFunding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need.
Tough times for cancer cell therapies
BackgroundSo far, no gene and cell therapies have been approved to treat solid tumours. European Biotechnology spoke with Karen Miller, SVP Pipeline Research at Adaptimmune plc, about promising candidates, and the art of circumventing supply chain bottlenecks caused by the COVID-19 pandemic.
Richter-Helm triples capacity at Bovenau site
Sponsored PublicationsRichter-Helm, a leading steadily growing Germany-based contract development and manufacturing organization (CDMO), offers excellent services in the continuously growing market of pharmaceutical biotechnology. Two additional bioreactors with capacities of 300 litres and 1,500 litres for microbial production will be added. This includes also the establishment of mid- and downstream processing and supporting utilities on a total area of about 10,000 m².
International control of hemp and cannabinoids
Sponsored PublicationsFor a plant that has been used for millennia, controls on the supply of psychoactive and non-psychoactive components extracted from cannabis are relatively recent, with global regulations starting in the 20th century with the International Opium Conventions. The current, and often conflicting, regulatory landscape has focused on definitions of hemp and cannabidiol (CBD). Reference materials are critical to defining the % ?9-THC in these products.